Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Illinois at Chicago
Kura Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Exelixis
University of Kansas Medical Center
Exelixis
Bristol-Myers Squibb
SCRI Development Innovations, LLC
Calithera Biosciences, Inc
Augusta University
University of Pittsburgh
National Cancer Institute (NCI)
Fondazione Ricerca Traslazionale